Facebook
Twitter
Telegram
Report an ErrorVBI Vaccines Balance Sheet 2011-2024 | VBIV
Annual Balance Sheet VBI Vaccines
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
28.1 M | -12.8 M | -92.4 M | -76.6 M | -27.9 M | -45.2 M | -54.6 M | -20.3 M | -26.8 M | -37.7 M | -48.5 M | -37.7 M | -20.4 M |
Long Term Debt |
50.8 M | 48.9 M | 28.4 M | 16.3 M | - | 12.9 M | 11.5 M | 12 M | - | - | - | - | - |
Long Term Debt Current |
976 K | 972 K | 839 K | 944 K | 642 K | 1.1 M | 1.6 M | - | - | - | - | - | - |
Total Non Current Liabilities |
3.69 M | 54 M | 33.8 M | 20.3 M | 4.19 M | 16.1 M | 12.6 M | 13.4 M | - | - | - | - | 48.6 M |
Total Current Liabilities |
75.7 M | 36.9 M | 32.6 M | 17.3 M | 29.8 M | 23.4 M | 13.2 M | 7.61 M | - | - | - | - | - |
Total Liabilities |
- | - | - | 37.7 M | 33.9 M | 39.5 M | 25.9 M | 21 M | 277 K | 249 K | 240 K | 710 K | 49.5 M |
Deferred Revenue |
7.28 M | 409 K | 526 K | 255 K | 882 K | 2.38 M | - | 34 K | - | - | - | - | - |
Retained Earnings |
-582 M | -490 M | -378 M | -309 M | -262 M | -208 M | -144 M | -105 M | -123 M | -65.7 M | -67.3 M | -63 M | -42 M |
Total Assets |
87 M | 155 M | 210 M | 209 M | 122 M | 138 M | 146 M | 105 M | 81.2 M | 157 M | 176 M | 185 M | 208 M |
Cash and Cash Equivalents |
23.7 M | 62.6 M | 122 M | 93.8 M | 44.2 M | 59.3 M | 67.7 M | 32.3 M | 12.5 M | 393 K | - | - | - |
Book Value |
87 M | 155 M | 210 M | 172 M | 88.3 M | 98.1 M | 120 M | 83.7 M | 80.9 M | 157 M | 175 M | 185 M | 158 M |
Total Shareholders Equity |
7.53 M | 64.2 M | 144 M | 172 M | 88.3 M | 98.1 M | 120 M | 83.7 M | 12.2 M | -9.43 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet VBI Vaccines
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
48.7 M | 50.8 M | 50.3 M | 47.8 M | 49.4 M | 48.9 M | 48.4 M | 21.2 M | 24.8 M | 28.4 M | 27.9 M | 27.5 M | 15.9 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 14.8 M | 14.8 M | 14.8 M | 12.4 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12 M | - | 12 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.32 M | 3.69 M | 3.7 M | 51.9 M | 53.9 M | 54 M | 53.5 M | 26.1 M | 30.5 M | 33.8 M | 31.1 M | 30.5 M | 19.1 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 4.19 M | 4.19 M | 4.19 M | 4.19 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 13.4 M | - | 13.4 M | 13.4 M | 1.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
9.62 M | 7.28 M | 6.97 M | 845 K | 649 K | 409 K | 597 K | 864 K | 649 K | 526 K | 324 K | 885 K | 882 K | 255 K | 255 K | 255 K | 255 K | 882 K | 882 K | 882 K | 882 K | 2.38 M | 2.38 M | 2.38 M | 74 K | - | - | - | - | 34 K | - | 34 K | 34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-600 M | -582 M | -582 M | -562 M | -517 M | -490 M | -468 M | -443 M | -398 M | -378 M | -360 M | -344 M | -326 M | -309 M | -309 M | -309 M | -309 M | -262 M | -262 M | -262 M | -262 M | -208 M | -208 M | -208 M | -208 M | -144 M | -144 M | -144 M | -144 M | -105 M | - | -105 M | -105 M | -81.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
75.4 M | 87 M | 101 M | 88.3 M | 128 M | 155 M | 172 M | 172 M | 194 M | 210 M | 224 M | 225 M | 223 M | 209 M | 209 M | 209 M | 209 M | 122 M | 122 M | 122 M | 122 M | 138 M | 138 M | 138 M | 138 M | 146 M | 146 M | 146 M | 146 M | 105 M | - | 105 M | 105 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.6 M | 23.7 M | 35.5 M | 20.8 M | 40.4 M | 62.6 M | 83.6 M | 82.4 M | 101 M | 122 M | 137 M | 135 M | 108 M | 93.8 M | 95.2 M | 93.8 M | 93.8 M | 44.2 M | 44.2 M | 44.2 M | 44.2 M | 59.3 M | 59.3 M | 59.3 M | 59.3 M | 67.7 M | 67.7 M | 67.7 M | 67.7 M | 32.3 M | 16.7 M | 32.3 M | 32.3 M | 12.5 M | - | - | - | 393 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
75.4 M | 87 M | 101 M | 88.3 M | 128 M | 155 M | 172 M | 172 M | 194 M | 210 M | 224 M | 225 M | 223 M | 209 M | 209 M | 209 M | 209 M | 122 M | 122 M | 122 M | 122 M | 138 M | 138 M | 138 M | 138 M | 146 M | 146 M | 146 M | 146 M | 105 M | - | 105 M | 105 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-5.47 M | 7.53 M | 19.9 M | 8.74 M | 45 M | 64.2 M | 83.8 M | 106 M | 130 M | 144 M | 160 M | 168 M | 180 M | 172 M | 172 M | 172 M | 172 M | 88.3 M | 88.3 M | 88.3 M | 88.3 M | 98.1 M | 98.1 M | 98.1 M | 98.1 M | 120 M | 120 M | 120 M | 120 M | 83.7 M | - | 83.7 M | 83.7 M | 12.2 M | - | - | - | -9.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency